Modality
Bispecific Ab
MOA
FGFRi
Target
EGFR
Pathway
STING
MCLPNH
Development Pipeline
Preclinical
~Oct 2011
→ ~Jan 2013
Phase 1
~Apr 2013
→ ~Jul 2014
Phase 2
~Oct 2014
→ ~Jan 2016
Phase 3
~Apr 2016
→ ~Jul 2017
NDA/BLA
~Oct 2017
→ ~Jan 2019
Approved
Apr 2019
→ Mar 2030
ApprovedCurrent
NCT03013928
2,657 pts·MCL
2019-04→2026-04·Not yet recruiting
NCT07585163
1,951 pts·PNH
2019-12→2030-03·Completed
NCT03287240
1,296 pts·PNH
2025-12→2026-07·Terminated
+1 more trial
7,757 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2025-10-235mo agoPh3 Readout· PNH
2026-04-055d awayPh3 Readout· MCL
2026-07-184mo awayPh3 Readout· PNH
2030-03-174.0y awayPh3 Readout· PNH
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Not yet…
Approved
Complet…
Approved
Recruit…
Approved
Termina…
Catalysts
Ph3 Readout
2025-10-23 · 5mo ago
PNH
Ph3 Readout
2026-04-05 · 5d away
MCL
Ph3 Readout
2026-07-18 · 4mo away
PNH
Ph3 Readout
2030-03-17 · 4.0y away
PNH
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03013928 | Approved | MCL | Not yet recr... | 2657 | CR |
| NCT07585163 | Approved | PNH | Completed | 1951 | 6MWD |
| NCT03287240 | Approved | PNH | Terminated | 1296 | Mayo |
| NCT08396558 | Approved | PNH | Recruiting | 1853 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR | |
| Capicilimab | Structure Ther | Phase 1 | EGFR |